The relationship between Sjogren’s syndrome, systemic sclerosis and lymphoproliferative diseases
- Authors: Vasil'ev V.I.1, Chal'tsev B.D.2, Gorodetskii V.R.2, Pal'shina S.G.2, Shornikova N.S.2, Anan'eva L.P.2, Gaiduk I.V.3, Kokosadze N.V.4, Probatova N.A.4, Pavlovskaia A.I.4, Rodionova E.B.5, Safonova T.N.6, Balabina A.A.7
-
Affiliations:
- Clinic MEDSI
- Nasonova Research Institute of Rheumatology
- Yevdokimov Moscow State University of Medicine and Dentistry
- Blokhin National Medical Research Center of Oncology
- Treatment Center
- Research Institute of Eye Diseases
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 92, No 12 (2020)
- Pages: 126-136
- Section: Articles
- URL: https://journals.rcsi.science/0040-3660/article/view/60277
- DOI: https://doi.org/10.26442/00403660.2020.12.200443
- ID: 60277
Cite item
Full Text
Abstract
Despite the large number of studies devoted to the study of systemic sclerosis (SSc), the high risk of developing lymphomas in this disease, the relationship of their development with certain subtypes of SSc and specific SSc-associated autoantibodies is still debated in the literature.
Aim. To study demographic, clinical, laboratory and immunological characteristics of patients with a combination of primary Sjogren’s syndrome (pSS) and SSc and diagnosed lymphoproliferative diseases (LPDs); to characterize morphological/immunomorphological variants and course of non-Hodgkin’s lymphomas (NHL), developing in patients with these rheumatic diseases (RDs).
Materials and methods. In 1998–2018 at the Nasonova Research Institute of Rheumatology, 13 patients with clinical and laboratory manifestations of pSS (12) and SSc (13) were diagnosed with various lymphoproliferative diseases (LPDs). In 3 cases, an induced RD was observed: 1 case of a diffuse, rapidly progressive form of SSc, 2 cases of pSS in combination with a limited form of SSc after chemotherapy and radiation therapy of Hodgkin’s lymphoma (1), B-cell NHL (1) and CR of the breast (1) respectively. The first 2 cases were excluded from the analysis, since the development of lymphomas is not pathogenetically associated with RD.
Results. Of 11 patients with LPDs, 10 after a long course of RDs were diagnosed with NHL [MALT lymphoma of the parotid salivary glands – 7, disseminated MALT lymphoma – 2, disseminated MALT lymphoma with transformation into diffuse large B-cell lymphoma (DLBCL) – 1]. RDs debuted with Raynaud’s phenomenon (RP) in 64.5% and pSS manifestations in 45.5% of patients. Stomatological manifestations of pSS were characterized by recurrent parotitis in 36%, significant parotid gland enlargement with massive infiltration of labial salivary glands (focus score >4) in 100%, severe xerostomia in 70%, extraglandular manifestations and lymphadenopathy in 50% of patients. The course of the SSc was characterized by mild RP with various types of capillaroscopic changes and mild lung changes and non-significant progression during long-term follow-up (median – 22 years). The entire spectrum of SSс specific antibodies (anticentromere antibodies – 60%, antibodies to ribonucleoprotease III – 30%, Pm/Scl – 10%), excepting antibodies to topoisomerase I, as well as pSS specific autoantibodies (antiRo/La – 70%, RF (rheumatoid factor) – 90%), were detected in patients with a combination of these RDs.
Conclusion. pSS is often combined with a limited form of SSc regardless of the type of autoantibodies detected. The presence of pSS, rather than SSc, is a high-risk factor for the development of NHL in this group of patients. The patients with pSS and SSc are characterized by a steady progression of pSS with a slow and mild course of SSc throughout the observation period. The development of severe stomatological manifestations and high immunological activity of pSS contribute to the development of localized MALT lymphomas (70%) and disseminated MALT lymphomas (30%) with primary lesions of the salivary glands and transformation into DLBCL in case of their late diagnosis. The optimal method for preventing the development of NHL in this group of patients is the early diagnosis of pSS, the appointment of alkylating cytotoxic agents and/or anti-B-cell therapy in the early stages of pSS. Given the possibility of transformation of localized NHL into DLBCL, for early diagnosis, minimally invasive surgical biopsies of significantly enlarged parotid salivary glands should be performed before glucocorticoids are prescribed. Detection of positive B-cell clonality and lymphoepithelial lesions in the parotid salivary gland is considered a predictor of MALT lymphoma development during follow-up. Localized and disseminated MALT lymphomas in patients with pSS and SSc respond well to therapy, in contrast to MALT lymphomas transformed into DLBCL.
Full Text
##article.viewOnOriginalSite##About the authors
V. I. Vasil'ev
Clinic MEDSI
Email: bodya92@inbox.ru
ORCID iD: 0000-0002-1425-8622
д.м.н., проф.
Russian Federation, MoscowB. D. Chal'tsev
Nasonova Research Institute of Rheumatology
Author for correspondence.
Email: bodya92@inbox.ru
ORCID iD: 0000-0003-4188-3578
аспирант
Russian Federation, MoscowV. R. Gorodetskii
Nasonova Research Institute of Rheumatology
Email: bodya92@inbox.ru
ORCID iD: 0000-0001-8428-1281
к.м.н., гематолог, вед. науч. сотр. лаб.
Russian Federation, MoscowS. G. Pal'shina
Nasonova Research Institute of Rheumatology
Email: bodya92@inbox.ru
ORCID iD: 0000-0003-3389-7064
к.м.н., науч. сотр. лаб.
Russian Federation, MoscowN. S. Shornikova
Nasonova Research Institute of Rheumatology
Email: bodya92@inbox.ru
к.м.н., зав. отд-нием
Russian Federation, MoscowL. P. Anan'eva
Nasonova Research Institute of Rheumatology
Email: bodya92@inbox.ru
ORCID iD: 0000-0002-3248-6426
д.м.н., проф., рук. лаб.
Russian Federation, MoscowI. V. Gaiduk
Yevdokimov Moscow State University of Medicine and Dentistry
Email: bodya92@inbox.ru
к.м.н., доц. каф
Russian Federation, MoscowN. V. Kokosadze
Blokhin National Medical Research Center of Oncology
Email: bodya92@inbox.ru
к.м.н., ст. науч. сотр.
Russian Federation, MoscowN. A. Probatova
Blokhin National Medical Research Center of Oncology
Email: bodya92@inbox.ru
ORCID iD: 0000-0002-3056-7062
д.м.н., проф., вед. науч. сотр.
Russian Federation, MoscowA. I. Pavlovskaia
Blokhin National Medical Research Center of Oncology
Email: bodya92@inbox.ru
ORCID iD: 0000-0003-0553-6122
к.м.н., вед. науч. сотр.
Russian Federation, MoscowE. B. Rodionova
Treatment Center
Email: bodya92@inbox.ru
к.м.н. зав. отд-нием
Russian Federation, MoscowT. N. Safonova
Research Institute of Eye Diseases
Email: bodya92@inbox.ru
к.м.н., вед. науч. сотр. отд-ния
Russian Federation, MoscowA. A. Balabina
Sechenov First Moscow State Medical University (Sechenov University)
Email: bodya92@inbox.ru
ассистент каф.
Russian Federation, MoscowReferences
- Zintzaras E, Voulgarelis M, Moutsopoulos HM. The Risk of Lymphoma Development in Autoimmune Diseases. A Meta-analysis. Arch Intern Med. 2005;14:2337-44.
- Сarlson S. The Fssociation of Malignancy with Rheumatic and Connective Tissue Disease. Semin Oncol. 1997;24(3):360-72.
- Логвиненко О.А., Васильев В.И. Ассоциация между болезнью Шегрена и лимфомами. Научно-практическая ревматология. 2006;3:67-76 [Logvinenko OA, Vasiliev VI. Association between primary Sjogren’s syndrome and lymphomas. Scientific and practical rheumatology. 2006;3:67-76 (In Russ.)].
- Smedby KE, Baecklund E, Askling J. Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2069-77. doi: 10.1158/1055-9965.EPI-06-0300
- Rosenthal AK, McLaughlin JK, Linet MS, Persson I. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis. 1993;52:531-3. doi: 10.1136/ard.52.7.531
- Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer. 1995;76:910-4.
- Chatterjee S, Domby GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum. 2005;52:2415-24.
- Daniels CE, Jett JR. Does interstial lung disease predispose to lung cancer? Curr Opin Pulm Med. 2005;11:431-7.
- Smedby KE, et al Autoimmune disorders and risk of nonHodgkin lymphoma sybtypes a pooled analisis within the IInterlymph Concortium. Blood. 2008;111(8):4029-38.
- Hill CL, Nguyen NM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis. 2003;62:728-31.
- Anaya J-M, Rojas-Villarrga A, Mantilla RD, et al. Polyautoimmunity in Sjogren Syndrome. Rheum Dis Clin N Am. 2016;42:457-72.
- Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant lymphoma in primary Sjogren’s syndrome: a multicenter retrospective, clinical study by the European Concerted Action on Sjogren’s Syndrome. Arthritis Rheum. 1999;42:1765-72.
- Васильев В.И., Пробатова Н.А., Тупицин Н.Н. и др. MALT-лимфомы при болезни Шегрена. Терапевтический архив. 2006;78(1):45-52 [Vasiliev VI, Probatova NA, Tupitsin NN, et al. MALT lymphomas in primary Sjogren’s syndrome. Therapeutic archive. 2006;78(1):45-52 (In Russ.)].
- LeRoy EC, Medsger TA. JR: Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-6.
- Den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis :an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;3:1747-55.
- Bloch RJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjogren’s syndrome. A clinical pathological and serological study sixty-two cases. Medicine (Baltimore). 1965;44:187-231.
- Medscer ThA. Sjogren’s Syndrome and Systemic Sclerosis. In book: Sjogren’s Syndrome. Clinical and Immunological Aspects. Eds. N. Talal, H. Moutsopoulos, S. Kassan. Springer-Verlag. 1987;182-9.
- Avouac J, Sordet C, Depinay, et al. Systemic sclerosis-associated Sjogren’s syndrome and relationship to the limited cutaneous subtype; Results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum. 2006;54:2243-9.
- Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological Heterogeneity in patients with anticentromere antibodies. J Rheumat. 2005;32:1488-94.
- Salliot C, Gottenberg JE, Bengoufa D, et al. Anticentromere antibodies identify patients with Sjogren’s syndrome and autoimmune overlap syndrome. J Rheumatol. 2007;34:2253-8.
- Moroi Y, Peebles C, Fritzler MJ, et al. Autoantibody to centromere(kinetochore) in scleroderma sera. Proc Natl Acad Sci USA. 1980;77:1627-31. doi: 10.1073/pnas.77.3.1627
- Старовойтова М.Н., Десинова О.В., Конева О.А. и др. Профиль аутоантител при системной склеродермии. Научно-практическая ревматология. 2016;54(4):418-23 [Starovoitova MN, Desinova OV, Koneva OA, et al. Profile of autoantibodies in systemic sclerosis. Rheumatology Science and Practice. 2016;54(4):418-23 (In Russ.)]. doi: 10.14412/1995-4484-2016-418-423
- Hudson M, Mahler M, Pope J, et al. Canadian Scleroderma Research Group, and Marvin Fritzler. Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with Systemic Sclerosis.
- Ананьева Л.П., Александрова Е.Н. Аутоантитела при системной склеродермии: спектр, клинические ассоциации и прогностическое значение. Научно-практическая ревматология. 2016;54(1):86-99 [Ananyeva LP, Aleksandrova EN. Autoantibodies in systemic sclerosis: spectrum, clinical associations, and prognostic value. Rheumatology Science and Practice. 2016;54(1):86-99 (In Russ.)]. doi: 10.14412/1995-4484-2016-86-99
- Чальцев Б.Д., Васильев В.И., Пальшина С.Г. и др. Клинические и лабораторные особенности болезни Шегрена с антицентромерными антителами. Научно-практическая ревматология. 2019;57(4):431-9 [Chaltsev BD, Vasilyev VI, Palshina SG, et al. Clinical and laboratory features of anticentromere antibody-positive Sjogren’s syndrome. Rheumatology Science and Practice. 2019;57(4):431-9 (In Russ.)]. doi: 10.14412/1995-4484-2019-431-439
- Baldini C, Mosca M, Della Rossa A, et al. Overlup of ACA-positive systemic sclerosis and Sjogren’s syndrome: a distinct clinical entity with mild organ involvement but at high risk lymphoma. Clin Exper Rheumatol. 2013;31:272-80.
- Gulati D, Kushner I, File E, Magrey M. Primary Sjogren’s Syndrome with anticentromere antibodies – a clinically distinct subset. Clinl Rheumatol. 2010;29:789-91.
- Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. IARC: Lyon, 2017; p. 1-523.
- Сафонова Т.Н., Васильев В.И., Лихванцева В.Г. Синдром Шегрена. Под ред. В.Г. Лихванцевой. Москва: изд-во Московского ун-та, 2013; с. 1-599 [Safonova TN, Vasiliev VI, Likhvantseva VG. Sjogren’s Syndrome. Ed. V.G. Likhvantseva. Moscow: publishing house of Moscow University, 2013; p. 1-599 (In Russ.)].
- Shiboski SC, Shiboski CN, Criswell LA, et al. American Cоllege of Rheumatology classification criteria for Sjogren’s syndrome: a data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012;64(4):475-87.
- Васильев В.И., Гайдук И.В., Пальшина С.Г. и др. Онкогематологические заболевания, дебютирующие с поражений больших слюнных желез в ревматологической практике. Совр. ревматология. 2019;13(1):44-51 [Vasilyev VI, Gaiduk IV, Palshina SG, et al. Primary hematologic malignancies with the onset of involvement of the major salivary glands in rheumatologic practice. Modern Rheumatology Journal. 2019;13(1):44-51 (In Russ.)]. doi: 10.14412/1996-7012-2019-1
- Varoczy L, Gergely L, Zeher M, et al. Malignant lymphoma-associated – a descriptive epidemiological study. Rhematol Int. 2002;22:233-7. doi: 10.1007/s0296-002-0229-4
- Zeineldine N, Khroury LE, Mosak J. Systemic sclerosis and malignancy: a revive current date. J Clin Med Res. 2016;8:625-32.
- Colaci M, Giuggioli D, Vaochi C, Ferri C. Heamatological Malignancies in Systemic Sclerosis Patients: Case Report and Review of the Literature. Hindawi Case Reports Rheumatol. 2017. doi: 10.1155/2017/6230138
- Boumia VK, Dlamanti KD, Vlachoyianopoulos PG, Moutsopoulos HM. Anticentromere antibody positive Sjogren’s syndrome. A retrospective descriptive analysis. Arthritis Res Ther. 2010;12:R47.
- Васильев В.И., Симонова М.В., Финогенова И.Ф. и др. Лимфопролиферативные заболевания и синдром Шегрена. Терапевтический архив. 1978;9:108-14 [Vasiliev VI, Simonova MV, Finogenova IF, et al. Lymphoproliferative diseases and Sjogren’s syndrome. Therapeutic archive. 1978;9:108-14 (In Russ.)].
- Jackson AE, Mian M, Kalpadacis C, et al. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicentrer, International Experience of 248 Patients (IELSG 41). Oncologist. 2015;20:1149-53.
- Kitagawa T, Shibasaki K, Toya S. Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjogren’s syndrome. Clin Rheumatol. 2012;31:105-12.
- Васильев В.И., Логвиненко О.А., Пробатова Н.А. и др. Роль биопсии околоушной слюнной железы в ранней диагностике лимфом при болезни Шегрена. Терапевтический архив. 2009;81(6):20-7 [Vasiliev VI, Logvinenko OA, Probatova NA, et al. The role of parotid salivary gland biopsy in the early diagnosis of lymphomas in Sjogren’s disease. Therapeutic archive. 2009;81(6):20-7 (In Russ.)].
- Arnaud L, Chryssostalis A, Terris B, et al. Systemic sclerosis and gastric MALT-lymphoma. Joint Bone Spine. 2006;73:105-8.
- Prochorec-Sobieszek M, Mielnik P, Wagner T, Chwalinska-Sadowska H. Mucosa-associated lymphoid tissue lymphoma (MALT) of salivary glands and scleroderma: a case report. Clin Rheumatol. 2004;23:348-50.
- Городецкий В.Р., Пробатова Н.А., Логвиненко О.А. и др. Ревматоидный артрит с синдромом Шегрена и MALT-лимфомой околоушной слюнной железы, ассоциированный с множественной миеломой. Описание случая и обзор литературы. Научно-практическая ревматология. 2010;3:103-6 [Gorodetsky VR, Probatova NA, Logvinenko OA, et al. Rheumatoid arthritis with Sjogren’s syndrome and MALT lymphoma of the parotid gland, associated with multiple myeloma: Description of a case and review of literature. Rheumatology Science and Practice. 2010;48(2):103-6 (In Russ.)]. doi: 10.14412/1995-4484-2010-1423
![](/img/style/loading.gif)